Is RENK’s stock better than Hensoldt’s? That is what analysts are saying. According to them, the transmission specialist is attractively valued at the current level. Hensoldt, on the other hand, is having problems converting its order backlog into revenue growth, leading to a significant reduction in its price target. In contrast, RZOLV Technologies shares have enormous upside potential. The Company aims to replace a toxic chemical used in gold extraction, thereby opening up a billion-dollar market. Development is nearly complete, and patents have been filed. In just a few months, RZOLV could become a hot takeover candidate. Meanwhile, takeovers currently appear to be a way for Novo Nordisk to replenish its drug pipeline, with the Danish company taking risks worth billions – Pfizer, take note.
RZOLV Technologies: Billion-dollar market in sight
Gold is currently shining brighter than ever. The price per troy ounce is solidly above USD 4,000. Despite all the euphoria, however, the extraction of the precious metal remains a dirty business. Take sodium cyanide, for example: this highly toxic chemical is used in over 90% of global production, as it can efficiently leach very finely distributed gold from low-grade ores. However, due to the health risks, there is growing public resistance in gold-producing regions, even leading to a complete ban in some cases. As a result, there is considerable pressure on industry to find an alternative. Whoever offers this alternative could earn billions. This is precisely the goal of RZOLV Technologies (TSXV:RZL).
This article is disseminated in partnership with Apaton Finance GmbH. It is intended to inform investors and should not be taken as a recommendation or financial advice.
For years, the Canadian company has been researching a safe alternative to sodium cyanide. And it seems to be on the home stretch. RZOLV has developed a water-based, non-toxic leaching formulation. The process is patent pending. The renowned testing service provider SGS and other external tests have confirmed that the solution is on par with cyanide in terms of yield and speed. Another important factor for gold companies is that the RZOLV product can be used in existing plants. Mine operators, therefore, do not need to purchase new equipment or machinery, but simply replace the sodium cyanide.
The potential for the RZOLV invention is huge, with the volume of the cyanide market estimated at USD 2.5 billion. In addition, new mines or old tailings piles can be developed in regions where cyanide is banned.
The next step is to conduct a 100-ton pilot test in Arizona. The Company has already raised CAD 2.85 million for this purpose. A dilutive capital increase is therefore not currently expected. If the pilot is successful, the cyanide alternative will go into mass production or be licensed out. A complete takeover by a chemical company also seems plausible. Given the potential, it might appear tempting to add a few RZOLV shares to one’s portfolio at the current price of around EUR 0.29. RZOLV Technologies’ shares have been listed on the TSX Venture Exchange in Canada since October 2025. They are now also listed in Germany.
Is RENK staging a comeback rally? Last week, the share price rose by over 7% and is now trading above EUR 50 again. It is still a long way off its October high of EUR 90, but the bottom may have been reached.
Bank of America currently sees a buying opportunity in RENK. The recommendation has been upgraded from “Underperform” to “Buy.” Analysts recently raised their price target from EUR 56.50 to EUR 60.50. Analysts consider the transmission specialist’s long-term goal of achieving an EBIT margin of around 21.5% on revenue of around EUR 3 billion to be feasible. The experts have raised their EBIT estimates for the coming years slightly.
However, analysts are not so optimistic about all German defense stocks. Hensoldt was downgraded from “Buy” to “Neutral.” Analysts have slashed their price target for Hensoldt shares from EUR 114 to EUR 77. The sensor specialist’s stock is currently trading at around EUR 69. Experts believe that Hensoldt is having problems converting its order backlog into revenue growth. This is likely to change only slowly. Therefore, the valuation level is already ambitious.
Novo Nordisk: Is the stock cheap or expensive?
Novo Nordisk’s stock is not currently valued ambitiously. However, after several profit warnings in the current year, it is at least reasonable to question whether the forecasts for the coming years will be met. At EUR 41, the share price is not far from its low for the year, but would have to more than double to reach its high for the year.
Filling the drug pipeline through acquisitions is risky. Pfizer has tried this in recent years and suffered several flops. Ironically, it was Pfizer that Metseras fought a bidding war with and lost.
Instead, Novo Nordisk struck a deal with Akero Therapeutics. The shareholders of the US biotech company approved the takeover a few days ago. Including possible milestone payments, the acquisition will cost Novo Nordisk up to USD 5.2 billion. Akero’s drug candidate Efruxifermin for the treatment of liver disease is in late-stage clinical development, but could still fail.
The Danish company has also suffered another setback in its own research recently. There had been hope that Novo Nordisk’s diabetes drug semaglutide would not only help with weight loss but could also be used to treat early-stage Alzheimer’s disease. After two years of research, the project has now been discontinued. Two extensive studies with 3,800 participants had yielded insufficient results.
Developments at RZOLV Technologies are extremely exciting. If the product delivers what it promises, the stock has enormous potential. Adding it to your portfolio could pay off as early as 2026. The RENK share appears to have bottomed out for the time being. Are the earnings estimates for Novo Nordisk realistic for the coming years? If so, the share would currently be cheap. However, the share price shows that the market currently has serious doubts.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
For full disclaimer information, please click here.
